Elevai Labs has received a conditional extension from Nasdaq to maintain its listing, following its failure to meet the minimum $1.00 bid price requirement since March 6, 2024. The company must complete a reverse stock split by December 26, 2024, and demonstrate compliance with the bid price rule by January 9, 2025.The company's compliance plan, presented at the October 22 Nasdaq hearing, includes raising $8 million through a public offering, obtaining shareholder approval for a reverse stock split, and completing a tender offer to exchange common stock for non-trading preferred stock by December 16, 2024.During the extension period until January 9, 2025, Elevai Labs must promptly notify Nasdaq of any significant events affecting its compliance status. The company has until November 22, 2024, to request a review of the Panel's determination by the Nasdaq Listing and Hearing Review Council, which would require a $15,000 review fee.

Elevai Labs has received a conditional extension from Nasdaq to maintain its listing, following its failure to meet the minimum $1.00 bid price requirement since March 6, 2024. The company must complete a reverse stock split by December 26, 2024, and demonstrate compliance with the bid price rule by January 9, 2025.The company's compliance plan, presented at the October 22 Nasdaq hearing, includes raising $8 million through a public offering, obtaining shareholder approval for a reverse stock split, and completing a tender offer to exchange common stock for non-trading preferred stock by December 16, 2024.During the extension period until January 9, 2025, Elevai Labs must promptly notify Nasdaq of any significant events affecting its compliance status. The company has until November 22, 2024, to request a review of the Panel's determination by the Nasdaq Listing and Hearing Review Council, which would require a $15,000 review fee.